LLY vs CRL
By Alex · Tickerpine
Eli Lilly and Company vs Charles River Laboratories Inte, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | CRL |
|---|---|---|
| Price | $1,220.28 | $284.37 |
| Market cap | $1.09T | $13.70B |
| P/E ratio | 41.0 | — |
| ROE | 102.29% | -7.52% |
| Profit margin | 33.53% | -5.96% |
| Revenue growth | 47.70% | -2.70% |
| Dividend yield | 0.57% | — |
| Beta | 0.51 | 1.38 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs CRL in plain English
- LLY is the bigger company — about 79.4× the market cap of CRL.
- LLY earns a higher return on equity (102% vs -8%).
- LLY is growing revenue faster (48% vs -3%).
- LLY pays a dividend (0.57%) while the other effectively doesn't.
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
CRL return calculator
See what $1,000 in Charles River Laboratories Inte would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.